ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer
A subset of non-small cell lung cancer (NSCLC), which does not have a druggable driver mutation, is treated with platinum-based cytotoxic chemotherapy, but it develops resistance triggered by DNA damage responses. Here, we investigated the effect of activation of STAT3 by cisplatin on anti-apoptotic...
Main Authors: | Eun Young Kim, Ji Ye Jung, Arum Kim, Yoon Soo Chang, Se Kyu Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-04-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558616303116 |
Similar Items
-
ABT-737 synergizes with Bortezomib to kill melanoma cells
by: Steven N. Reuland, et al.
Published: (2012-02-01) -
BCL2L10 Is Overexpressed in Melanoma Downstream of STAT3 and Promotes Cisplatin and ABT-737 Resistance
by: María Josefina Quezada, et al.
Published: (2020-12-01) -
Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas
by: Jain, H, et al.
Published: (2012) -
Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas.
by: Harsh Vardhan Jain, et al.
Published: (2014-01-01) -
Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.
by: Fitzgerald, D, et al.
Published: (2011)